What is Tesamorelin?

Tesamorelin is a synthetic peptide analogue of growth hormone-releasing hormone (GHRH). It’s designed to mimic the effects of naturally occurring GHRH, which stimulates the pituitary gland to release growth hormone. Tesamorelin is mainly studied for its effects on GH regulation and associated metabolic pathways in experimental research models.

What is GHRH?

Growth hormone-releasing hormone (GHRH) is a peptide produced in the hypothalamus. It plays a key role in:

• Stimulating growth hormone (GH) release from the pituitary gland

• involved in pathways related to protein and lipid metabolism

• Participates in cellular signaling processes linked to growth and recovery

• Plays a role in circadian regulation of GH release patterns in research settings

Because native GHRH is rapidly broken down in the body, researchers have created more stable analogues like Tesamorelin to allow for extended study.

How Tesamorelin is Being Studied:

1. Observed Effects on Growth Hormone Secretion

   Tesamorelin binds to GHRH receptors on the pituitary gland, triggering a natural increase in GH secretion. In lab settings, this has allowed researchers to examine the downstream effects of elevated GH, such as changes in lipid metabolism and muscle development.

   (Reference: Falutz et al., 2010)

   
   

2. Effects on Visceral Adipose Tissue

   One of the most studied effects of Tesamorelin is its ability to reduce visceral fat, particularly in specific research populations. In multiple trials, Tesamorelin has been associated with measurable decreases in abdominal fat without significant impact on subcutaneous fat.

   (Reference: Stanley et al., 2011)

   
   

3. Observed Effects on Glucose Pathways

   Unlike some GH-related peptides that may affect glucose metabolism, Tesamorelin has been observed in some models to preserve or have minimal impact on insulin sensitivity, making it a key subject in metabolic research.

   (Reference: Guaraldi et al., 2012)

   
   

References

• Falutz, J., et al. (2010). Metabolic effects of a growth hormone–releasing factor in patients with HIV. The New England Journal of Medicine, 363(8), 716–726.

• Stanley, T.L., et al. (2011). Effects of tesamorelin on visceral fat and metabolic parameters in HIV-infected patients. Journal of Clinical Endocrinology & Metabolism, 96(9), 2738–2745.

• Guaraldi, G., et al. (2012). Tesamorelin: a growth hormone-releasing factor analogue for management of HIV-associated lipodystrophy. Drugs of Today, 48(11), 745–752.

All products sold by Direct Peptides are strictly for laboratory research purposes only. They are not intended for human or animal consumption, medical, or therapeutic use. The information provided on this website is for educational and informational purposes only.